Basci N E, Brosen K, Bozkurt A, Isimer A, Sayal A, Kayaalp S O
Department of Pharmacology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Br J Clin Pharmacol. 1994 Nov;38(5):463-5. doi: 10.1111/j.1365-2125.1994.tb04383.x.
A mephenytoin test was carried out in 106 unrelated healthy Turkish volunteers. Racemic mephenytoin was coadministered with either debrisoquine or sparteine. The S/R mephenytoin ratio ranged from < 0.1 to 0.73 in 105 subjects, accordingly phenotyped as extensive metabolisers. One subject had an S/R mephenytoin ratio of 1.02, showing that he was a poor metaboliser of mephenytoin (0.94%, confidence interval 0.25% and 13.65%). In 48 subjects, the metabolic ratios of debrisoquine and sparteine were correlated significantly (rs = 0.61, P < 0.001).
在106名无亲缘关系的健康土耳其志愿者中进行了美芬妥英试验。消旋美芬妥英与地布喹或司巴丁联合给药。105名受试者的S/R美芬妥英比值范围为<0.1至0.73，因此被表型为快代谢型。一名受试者的S/R美芬妥英比值为1.02，表明他是美芬妥英的慢代谢型（0.94%，置信区间0.25%和13.65%）。在48名受试者中，地布喹和司巴丁的代谢比值显著相关（rs = 0.61，P < 0.001）。
